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Abstract
Background: Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes encode cytosolic and
mitochondrial enzymes that catalyze the conversion of isocitrate to a-ketoglutarate. Acquired somatic mutations of
IDH1 and IDH2 have recently been reported in some types of brain tumors and a small proportion of acute
myeloid leukemia (AML) cases.
Methods: Two-hundred and thirty newly diagnosed AML patients were analyzed for the presence of IDH1 and
IDH2 heterozygous mutations by polymerase chain reaction-denaturing high performance liquid chromatography
(PCR-DHPLC) followed by direct sequencing. Clinical and biological characteristics were analyzed and correlated to
the IDH mutational status. Coexisting mutations such as FLT3, PML-RARA, RAS, AML1, and NPM1 mutations were
additionally explored.
Results: The prevalence of IDH1 and IDH2 mutations was 8.7% (20/230) and 10.4% (24/230), respectively. Six
missense mutations were identified among IDH1-mutated cases; p.R132H (n = 8), p.R132C (n = 6), p.R132S (n = 2),
p.R132G (n = 2), p.R132L (n = 1), and p.I99M (n = 1). Two missense mutations were found in IDH2-mutated cases;
p.R140Q (n = 20) and p.R172K (n = 4). No patients had dual IDH1 and IDH2 mutations. About 18% of AML with
normal cytogenetics and 31% of acute promyelocytic leukemia had IDH mutations. Half of the IDH-mutated cohort
had normal karyotype and the major FAB subtype was AML-M2. Interestingly, IDH1- and IDH2-mutated cases
predominantly had NPM1 mutations (60-74%) as compared to the wild type (P < 0.001). Very few IDH-mutated
cases had FLT3 and/or RAS abnormalities and none of them had AML1 mutations. Older age and higher median
platelet counts were significantly associated with IDH2 mutations although the clinical impact of either IDH1 or
IDH2 mutations on patients’ overall survival could not be observed.
Conclusion: Overall, 19% of newly diagnosed AML patients had alterations of IDH genes. No patients concurrently
carried both IDH1 and IDH2 mutations suggesting that these mutations were mutually exclusive. NPM1 mutation
appears as a major coexisting genetic mutation in IDH-mutated patients. Our present data failed to support the
prognostic relevance of IDH mutations although alterations of these metabolic genes potentially have an important
role in leukemia development.
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Acute myeloid leukemia (AML) is a malignant hemato-
logic disorder characterized by abnormal expansion of
differentiation-defective myeloid cells [1]. Various chro-
mosomal aberrations have been identified in AML
patients and are uniquely associated with distinct clini-
cal entities and prognostic relevance [2]. Although 40-
50% of AML cases do not carry any detectable chromo-
somal abnormalities, a fraction of them are found to
have mutations of genes that normally function in cell
proliferation, differentiation, and survival such as FLT3,
NPM1, RAS, WT1,a n dAML1 [3,4]. Moreover, through
a rapid whole genome sequencing approach, it is now
evident that at least half of the AML cases with normal
karyotype have readily identifiable genomic abnormal-
ities [5].
Alteration of cellular metabolism has recently been
proposed as a novel oncogenetic mechanism [6,7]. Isoci-
trate dehydrogenase (IDH) is one the enzymes that, if
defective, lead to abnormal cellular metabolism [8,9].
There are three IDH isoforms; IDH1 is in the cytoplasm
whereas IDH2 and IDH3 are localized in the mitochon-
dria [9,10]. IDH1 and IDH2 genes encode enzymes that
catalyze oxidative decarboxylation of isocitrate into a-
ketoglutarate (a-KG) by utilizing nicotinamide adenine
dinucleotide (NAD) or NAD phosphate (NADP) as a
cofactor to generate NADH or NADPH, respectively
[11]. In 2008, a novel mutation of IDH1 gene was firstly
described in patients with glioblastoma multiforme
(GBM). Subsequent studies additionally identified such
mutations in > 70% of young adults with low-grade
glioma and 80% of patients with secondary GBM
[12-14]. Meanwhile in 2009, IDH1 mutation was
reported in a subset of AML patients lacking specific
chromosomal aberrations [5] and in 2010, IDH2 muta-
tion was identified in AML, myelodysplastic syndrome
(MDS), and myeloproliferative neoplasms (MPN)
[15-17]. The worldwide frequencies of IDH1 and IDH2
mutations in newly diagnosed AML patients range from
2% to 14% and 1% to 19%, respectively, with the muta-
tions mostly restricted to codon R132 of IDH1 and
codon R140 of IDH2 [5,15,18-32]. Biochemical and
molecular analyses reveal that mutations at the evolutio-
narily conserved site of IDH lead to interruption of the
normal ability of enzyme to bind substrates and subse-
quent acquisition of novel enzymatic activity resulting in
a substantial increase of oncometabolite R(-) -2-hydro-
xyglutarate (2HG) through a-KG conversion [8,19,20].
The accumulation of elevated 2HG induces global DNA
hypermethylation and interruption of hematopoietic
differentiation [33,34].
In the present study, we aimed to characterize IDH1
and IDH2 mutations in newly diagnosed AML patients
and investigate their correlations to other parameters
such as clinical and hematologic characteristics, cytoge-
netics and additional genetic mutations.
Methods
Leukemia samples
Leukemic samples from 230 newly diagnosed AML
cases were consecutively recruited into the study. Clini-
cal and biological characteristics were collected includ-
ing clinical history, complete blood counts, peripheral
blood (PB) smear, bone marrow (BM) studies, flow cyto-
metric immunophenotyping, and chromosome analysis.
Mononuclear cells (MNC) were isolated from the leuke-
mic samples by Ficoll-Hypaque density-gradient centri-
fugation and subsequently used for molecular analysis.
Twenty consented normal individuals were used as con-
trols. Patients were treated according to the standard
AML regimen which included idarubicin and cytarabine
induction therapy followed by high-dose cytarabine-
based consolidation phase. This study was approved by
the Ethical Committee for Human Research, Faculty of
Medicine Siriraj Hospital, Mahidol University.
Mutational analysis of IDH1 and IDH2
Genomic DNA was extracted using standard phenol-
chloroform method or Gentra Puregene Blood Kit (Qia-
gen, Hidden, Germany) according to the manufacturer’s
protocol. DNA amplicons harbouring exon 4 of IDH1
and IDH2 were amplified by polymerase chain reaction
(PCR) using the primer pair; IDHIf (5’-AGCTC
TATATGCCATCACTGC-3’), IDH1r (5’-AACATG-
CAAAATCACATTATTGCC-3’), IDH2f(5’- AATTTTA
GGACCCCCGTCTG-3’), and IDH2r (5’-CTGCAGA-
GACAAGAGGATGG-3’) [13]. PCR reactions were per-
formed in a total volume of 20 μL containing 50 ng of
genomic DNA, PCR master mixture consisting of 1x
Phusion
®HF Buffer (F-520), 200 μMd N T P s ,0 . 5μMo f
each primer, 0.02 U/μL Phusion
® DNA polymerase, and
Milli-Q water. The PCR was carried out in a Perkins
Elmer PCR2400 thermal cycler (Applied Biosystems,
Foster City, CA) using the following steps: initial dena-
turation at 98°C for 30 seconds (sec), 35 cycles at 98°C
for 10 sec, 60°C for 30 sec. and 72°C for 30 sec, and
final extension at 72°C for 5 minutes (min). Both ampli-
cons were screened for heterozygous mutations by dena-
turing high-performance liquid chromatography
(DHPLC) on a WAVE 3500HT with DNASep
® HT car-
tridge technology (Transgenomic Inc, Omaha, NE,
USA). The optimized condition and temperature were
predicted by the Navigator™ software to determine
chromatographic peak pattern. PCR crude sample was
injected into DHPLC column and the optimal tempera-
ture for IDH1 was 58.5°C and IDH2 was 64°C. Each
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reference. The sensitivity of our assay was determined
by performing a dilution series containing a different
percentage (%) of mutant and wild-type IDH concentra-
tions. Abnormal DHPLC peaks could be clearly detected
in 50%, 20%, 10%, 5%, and 3.33% dilutions. The muta-
tional chromatograms were re-amplified in an indepen-
dent PCR reaction and further subjected to direct
sequencing. The sequences were compared to the wild-
type IDH1 and IDH2 cDNA (GenBank Accession num-
ber, NM_005896.2 and NM_002168.2, respectively) [25].
Analysis of additional molecular aberrations
Mutational analyses of FLT3, PML-RARA, RAS, AML1,
and NPM1 were performed according to our previously
d e s c r i b e dm e t h o d[ 3 5 - 3 9 ] .B r i e f l y ,t h eD N Ao rR N A
was extracted, then the genes of interest were amplified
and detected by gel electrophoresis (FLT3), denaturing
high performance liquid chromatography (DHPLC)
(NPM1), single-strand conformational polymorphism
(SSCP) (RAS and AML1). For PML-RARA,t h ec D N A
was synthesized and reverse transcriptase-polymerase
chain reaction (RT-PCR) performed.
Statistical analysis
The relationship between IDH mutations and various
patient characteristics such as age, Hb count, WBC
count, platelet count, and percentages of blasts was deter-
mined by the student t-test, equal variances not assumed
for continuous variables. Categorical variables such as
FAB classification, cytogenetics, and test. The Kaplan-
Meier method and the log-rank test were utilized to esti-
mate the distribution of OS [40]. For all analyses, a
p-value of less than 0.05 was considered statistically
significant. All reported p-values were 2-sided.
Results
Frequency and type of IDH1 and IDH2 mutations
In a total cohort of 230 consecutive AML patients (36
acute promyelocytic leukemia (APL) and 194 non-APL),
44 patients with IDH mutation were identified (19.13%)
by DHPLC showing abnormal chromatogram patterns
that were different from the wild-type profiles. These
mutations were further confirmed by sequencing analysis
(Figure 1). Twenty IDH1 mutations (8.7%) included six
missense mutations leading to amino acid (AA) substitu-
tion with different frequencies: c.G395A; p.R132H in 8
cases (40.0%), c.C394T; p.R132C in 6 cases (30.0%), c.
C394A; p.R132S in 2 cases (10.0%), c.C394G; p.R132G in
2 cases (10.0%), c.G395T; p.R132L in 1 cases (5.0%), and
c.A297G; p.I99M in 1 cases (5.0%) (Table 1). In addition,
one silent polymorphism (c.315 G > T; IDH1
G105G)w a s
observed in 3 patients (1.30%). Twenty-four IDH2 muta-
tions (10.4%) included two missense mutations with
different frequencies: c.G419A; p.R140Q in 20 cases
(83.3%) and c.G515A; p.R172K in 4 cases (16.7%). All
patients with the mutations were heterozygous and
retained a wild-type allele (Figure 1). No mutated patients
harbored dual mutations of both genes, indicating that
these mutations are mutually exclusive.
Clinical parameters and morphologic subtypes of
patients with IDH1 or IDH2 mutations
Twenty IDH1-mutated patients showed no significant dif-
ferences in age, hemoglobin level, WBC counts, platelet
counts or percentages of blasts as compared to the IDH1
wild-type group, although a trend towards more females
was observed (15 females vs 5 males; P = .058). Twenty-
four IDH2-mutated patients also showed no significant
differences in sex, WBC counts or percentages of blasts
but an older age (49.5-year vs. 43-year; P = .001), a higher
platelet count (59 vs. 45 × 10
9/L; P = .048), and a trend
Figure 1 Detection of IDH1 and IDH2 mutations by DHPLC and
direct sequencing analysis. DHPLC patterns shows a suspicious
peak in cases with IDH1 or IDH2 mutations as compared to cases
with the wild type (WT); Six missense IDH1 mutations; R132H,
R132C, R132S, R132G, R132L, and I99M and 1 silent mutation
(G105G), and 2 missense IDH2 mutations; R140Q and R172K, are
demonstrated. (Abbreviation: C, cysteine; G, glycine; H, histidine; I,
isoleucine; K, lysine; L, leucine; M, methionine; Q, glutamine; S,
serine).
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P = .059) were observed in the IDH2-mutated group as
compared to the wild-type group (Tables 2 and 3).
Among IDH1-mutated cases, the majority was classified
as AML with maturation (AML M2) (13/20 cases, 65%)
followed by APL (5/20 cases, 25%). None of the cases
with APL, acute monoblastic or monocytic leukemia,
acute erythroid leukemia, and acute megakaryoblastic leu-
kemia was found among IDH1-mutated group. Similarly,
AML with maturation (AML M2) was the most common
subtype among the IDH2-mutated group (11/24 cases,
46%) (Table 3). The second most common subtypes were
APL (6/24 cases, 25%) and acute myelomonocytic leuke-
mia (6/24 cases, 25%). The OS of patients with or with-
out IDH1 or IDH2 mutations did not differ among the
entire series of AML patients and AML patients with
normal cytogenetics (P = 0.200 and 0.272, respectively).
No significant difference was demonstrated in subgroups
of younger patients (age < 60) and patients with/without
additional mutations as compared to the wild-type
patients (P = 0.471 and 0.812, respectively).
Chromosomal patterns and additional molecular
aberrations in patients with IDH1 or IDH2 mutations
Cytogenetic information was available in 226 of 230
patients, 126 patients (55.75%) of whom had normal
karyotype and 100 patients (44.25%) had an aberrant
karyotype. Of 20 AML cases with IDH1 mutation, 11
cases had normal karyotype (55%). In the aberrant kar-
yotype, we found 5 cases with t(15;17) chromosome
translocation, 2 cases with del(9q), and 1 case with tris-
o m y8( T a b l e2 ) .O f2 4c a s e sw i t hIDH2 mutation, 12
cases had normal karyotype (50%). In the aberrant kar-
yotype, we observed 6 cases with t(15;17), 2 cases were
IDH2 R172K harboring trisomy 11, 1 case with trisomy
8, 1 case with t(8;21), and 1 case with del(12)
(p12.1p13.1) (Table 3).
IDH1 mutations were significantly associated with
NPM1 mutation as compared with wild-type cases (14/
19, 74% vs. 45/185, 24%; P < 0.001)(Table 4). Some
cases had additional mutations including FLT3-ITD,
FLT3-TKD, NRAS, and PML-RARA. IDH2 mutations
were also significantly associated with NPM1 mutations
when compared with the respective wild-type cases (12/
20, 60% vs. 47/184, 26%; P < 0.001)(Table 4). AML1
mutations were not observed in any mutated IDH1 or
IDH2 patients.
Discussion
In the present study, we developed a screening DHPLC
method followed by sequencing analysis to detect and
confirm the presence of IDH mutations in newly diag-
nosed AML patients. Twenty cases of IDH1 mutations
and 24 cases of IDH2 mutations were discovered among
t h ee n t i r en e w l yd i a g n o s e dA M Lc o h o r t .P r e v i o u s
reports from the Asia continent were available from two
countries, i.e. Taiwan [18] and China [28,31,32] while
the Western studies were from USA [5,15,20,22,29],
Canada [19], France [41], Germany [21,23,25,27], the
Netherlands [24], and UK [26,30] (Table 5). The overall
frequency of IDH mutations appears to vary between 2-
14% for IDH1 and 1-19% for IDH2 from most Western
reports [5,15,19,27,29,30,41]. Worthy of note, the fre-
quency of IDH1 mutations in our population of 8.4%
was comparable to 8.5% in the first study reported by
Mardis et al. in 2009 [5] although these figures were
somewhat higher than those of the Chinese AML stu-
dies (5.5%, 5.6%, 6.3%, and 3.6%) [18,28,31,32]. The fre-
quency of IDH2 mutations of 10.4% in our cases was
also slightly higher than the only available IDH2 study
from Asia (8.3%, 4/48) [28]. The frequency discrepancies
among various studies may reflect the variable inclusion
criteria of the study samples, the variable sensitivity of
the detection assays, the selective inclusion or exclusion
of certain IDH aberrations or the true racial differences.
IDH1 mutations consisting of six different amino acid
exchanges at p.R132 (n = 19) and p.I99M (n = 1) were
identified. Within the p.R132 group, arginine was
replaced by histidine (R132H) in most cases (n = 8,
4 0 % ) ,f o l l o w e db yc y s t e i n e( R 1 3 2 C ;n=6 ,3 0 % ) ,s e r i n e
(R132S; n = 2, 10%), glycine (R132G; n = 2, 10%) and
leucine (R132L, n = 1, 5%). This pattern was extremely
different to the mutation pattern reported in glioma,
where R132H was predominant observed in 88% of all
cases while R132C present in only 4.5% [13]. To date,
results from structural and functional assays by several
multicenter trials suggested that IDH1 R132, which
resides at the active site of enzyme substrate affinity,
Table 1 Type of IDH1 and IDH2 mutations identified in
230 AML patients
Mutation Nucleotide
change
Predicted protein
change
No. of
patients
IDH1*
c.G395A CGT-CAT p.R132H 8
c.C394T CGT-TGT p.R132C 6
c.C394A CGT-AGT p.R132S 2
c.C394G CGT-GGT p.R132G 2
c.G395T CGT-CTT p.R132L 1
c.A297G ATA-ATG p.I99M 1
IDH2**
c.G419A CGG-CAG p.R140Q 20
c.G515A AGG-AAG p.R172K 4
Abbreviation: AML, acute myeloid leukemia; C, cysteine; G, glycine; H, histidine;
I, isoleucine; K, lysine; L, leucine; M, methionine; Q, glutamine; S, serine
*IDH1 nucleotide numbering based upon the National Center for
Biotechnology Information sequence NM_005896.2
**IDH2 nucleotide numbering based upon the National Center for
Biotechnology Information sequence NM_002168.2
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[9,11,20,33]. In the p.I99M case, isoleucine was substi-
tuted by methionine which was recently identified as a
novel missense mutation in the Chinese cohort by Zou
et al [28]. The same study revealed that this evolution-
ary point mutation was also located in the substrate
binding site of enzyme and may drive pathogenesis;
however, the exact mechanism needs further investiga-
tion. In addition, we detected one silent polymorphism
(IDH1
G105G) in 3 cases (1.3%). Wagner et al. [21] pre-
viously reported that IDH1
G105G allele conferred an
adverse prognostic impact to patients’ survival.
The identified IDH2 mutations involved two different
types of amino acid substitution spanning exon 4 of the
IDH2 gene at arginine 140 and arginine 172. Of note,
the former arginine was replaced by glutamine (R140Q;
n = 20, 83.3%) and the latter arginine was replaced by
lysine (R172K; n = 4, 16.7%). Our study was similar to
previous studies which revealed that more than 80% of
the IDH2 mutations involved R140 [15]. R172 mutations
were profoundly associated with biological insights and
clinical outcome [15,20] while R140 has not been
addressed to associate with any prognostic significance
in AML [23]. Therefore, functional validation should be
employed to define whether R140 plays a significant
role in AML pathogenesis or is simply a genuine
polymorphism.
IDH1 mutation was previously reported to be strongly
associated with normal karyotype or intermediate risk
karyotype AML [5,15,25,41]. Noticeably, our present
Table 2 Characteristics of AML patients with a wild type or mutated IDH1
Variable All cases IDH1
m IDH1
wt P*
No. of cases 230 20 210
No. of males/females 101/129 5/15 96/114 .058
Age, years .860
†
Median (range) 44 (13-86) 42.5 (15-85) 45 (13-86)
Hemoglobin, g/dL .311
†
Median (range) 7.8 (1.4 -14.5) 7.4 (2.9 - 10.8) 7.85(1.4-14.5)
WBC count, x10
9/L .323
†
Median (range) 27.7 (0.6 -494.4) 26.9 (1.0 -190.9) 27.7 (0.6 -494.4)
Platelet, x10
9/L .923
†
Median (range) 46 (1.8-965) 56 (16.9 - 386) 45.5 (1.8-965)
Percentage of blasts .738
†
Median (range) 70.19 (6.69-95.44) 75.8 (13.3-91.4) 69.77 (6.69-95.44)
Patients (%) Patients (%)
FAB classification
M0 3 1 (5) 2 (0.9)
M1 51 1 (5) 50 (23.8)
M2 76 13 (65) 63 (30)
M3 36 5 (25) 31 (15)
M4 34 0 (0) 34 (16)
M5 21 0 (0) 21 (10)
M6 8 0 (0) 8 (3.8)
M7 1 0 (0) 1 (0.5)
Patients (%) Patients (%)
Cytogenetics
Abnormal
t(15;17) 36 5 (25) 31 (15) .184
t(8;21) 20 0 (0) 20 (10) .149
inv(16) 3 0 (0) 3 (1) .760
trisomy 8 4 1 (5) 3 (1) .307
Other trisomies 7 0 (0) 7 (3) .524
All others including monosomies, deletions or combination of these 22 2 (10) 20 (10) .594
Complex karyotype 8 0 (0) 8 (4) .477
Normal 126 11 (55) 115 (55) .587
Abbreviation: IDH1
m, IDH1 mutated; IDH1
wt, IDH1 wild type
* Fisher exact test unless otherwise indicated;
†, the student t- test
Chotirat et al. Journal of Hematology & Oncology 2012, 5:5
http://www.jhoonline.org/content/5/1/5
Page 5 of 10study found that although IDH1 mutation predomi-
nantly had normal karyotype (n = 11/20), various aber-
rant karyotype were also found (n = 8/20) including 5
cases of t(15;17). Similarly, although half of IDH2-
mutated cases had normal karyotype (n = 12/24), 6
cases had t(15;17). Our study showed a higher frequency
of IDH mutations in APL with t(15;17) (n = 11/36 cases,
31%) than most other APL series reported [5,18,24,
27,29,32] (Table 6). The prognostic significance of IDH
mutations in APL patients needs further studies.
To explore if other genetic mutations coexist in AML
cases with IDH mutations, we performed mutation ana-
lysis of various different genes, i.e. FLT3, NPM1, NRAS
and AML1. IDH1 mutations were found to be most fre-
quently accompanied by NPM1 mutations (74% of the
cases; P < 0.001). Previous studies also demonstrated
that IDH1 mutation was significantly associated with
NPM1 mutation, ranging from 12.5% to 67% as com-
pared to the wild-type IDH1 cases [5,18,24,25,27,41].
Similarly, IDH2 mutations were significantly associated
with NPM1 mutations (60% of the cases; P <0 . 0 0 1 )
which were comparable to other reports [24-26]. No sig-
nificant association was found with other molecular
alterations including FLT3-ITD, FLT3-TKD, NRAS and
AML1 although FLT3-ITD was also frequently found
co-existing with IDH1 mutation in some studies [15,25].
Meanwhile, other authors also showed no significant
correlation between either IDH1 or IDH2 mutation and
FLT3-TKD, NRAS and AML1 mutation [5,18,24,
27,30,41].
Table 3 Characteristics of AML patients with a wild type or mutated IDH2
Variable All cases IDH2
m IDH2
wt P*
No.of cases 230 24 206
No.of males/females 101/129 11/13 90/116 .504
Age, years .001
†
Median (range) 44 (13-86) 49.5 (38-80) 43 (13-86)
Hemoglobin, g/dL .059
†
Median (range) 7.8 (1.4 - 14.5) 9.25 (4.7-12.6) 7.7 (1.4 - 14.5)
WBC count, × 10
9/L .789
†
Median (range) 27.7 (0.6 - 494.4) 29.73 (0.89-222) 26.4 (0.6 - 494.4)
Platelet, x10
9/L .048
†
Median (range) 46 (1.8-965) 59 (11-965) 45 (1.8-852)
Percentage of blasts .133
†
Median (range) 70.19 (6.69-95.44) 61.79 (32.52-95.03) 71.66 (6.69-95.44)
Patients (%) Patients (%)
FAB classification
M0 3 0 (0) 3 (1.5)
M1 51 1 (4) 50 (24)
M2 76 11 (46) 65 (31)
M3 36 6 (25) 30 (15)
M4 34 6 (25) 28 (14)
M5 21 0 (0) 20 (10)
M6 8 0 (0) 8 (4)
M7 1 0 (0) 1 (0.5)
Patients (%) Patients (%)
Cytogenetics
Abnormal
t(15;17) 36 6 (25) 30 (14.6) .150
t(8;21) 20 1 (4.2) 19 (9.2) .355
inv(16) 3 0 (0) 3 (1.5) .717
trisomy 8 4 1 (4.2) 3 (1.5) .358
Other trisomies 7 2
‡ (8.2) 5 (2.4) .158
All others including monosomies, deletions or combination of these 22 1 (4.2) 21 (10.2) .301
Complex karyotype 8 0 (0) 8 (3.8) .408
Normal 126 12 (50) 114 (55.3) .388
Abbreviation: IDH2
m, IDH2 mutated; IDH2
wt, IDH2 wild type
* Fisher exact test unless otherwise indicated;
†, Student t- test;
‡, 2 cases of trisomy11 harboring IDH2 R172K mutation
Chotirat et al. Journal of Hematology & Oncology 2012, 5:5
http://www.jhoonline.org/content/5/1/5
Page 6 of 10With respect to clinical and hematologic parameters,
IDH1 mutated cases were frequently females rather than
males (15 cases vs. 5 cases) which was similar to the
German study by Schnittger et al. [27]. Interestingly, we
observed that both IDH1 and IDH2 mutations were pre-
dominantly found in AML with maturation (AML-M2;
n = 24/44) and acute promyelocytic leukemia (APL)
(AML-M3; n = 11/44) which were different from AML-
M1 as reported by others [5,27,30]. Interestingly, the
frequency of IDH2 mutation coexisting in AML-M4 of
25% in our study was comparable with 27% in the find-
ing reported by Thol et al. [23]. IDH1 or IDH2 muta-
tions did not significantly impact survivals when the
whole AML cohort or AML with normal karyotype ana-
lyzed (P = 0.200 and 0.272). We therefore further ana-
lyzed OS according to age and NPM1 status.
Unfortunately, we could not find a significant difference
between IDH1-a n dIDH2-mutated and wild-type cases
(P = 0.471 and .812) either in the younger age group (<
60 years) or the NPM1-mutated genotype. Our study
was consistent with some studies that revealed no
impact of IDH mutations on the OS of AML cases
although other studies suggested that IDH1 or IDH2
mutations conferred an adverse effect among AML with
normal karyotype or AML with favorable genotype
(NPM1 mutated/FLT3 wild type) [15,25-27,41]. IDH1
Table 4 Comparison of additional gene mutations in AML patients with and without IDH1 and IDH2 mutations
Additional gene
mutations
IDH1
m
n = 20 No.
(%) IDH1
wt n = 210 No. % P* IDH2
m n = 24 No. % IDH2
wt n = 206 No. % P*
NPM1 <.001 <.001
Wild type 5 26% 140 76% 8 40% 137 75%
Mutated 14 74% 45 24% 12 60% 47 25%
FLT3-ITD .34 .63
Absent 14 82% 108 74% 13 76% 109 75%
Present 3 18% 38 16% 4 24% 37 25%
FLT3-TKD .59 .59
Absent 15 94% 133 91% 15 94% 133 91%
Present 1 6% 33 9% 1 6% 33 9%
AML1 .09 .09
Wild type 15 100% 147 86% 17 100% 145 86%
Mutated 0 0% 23 14% 0 0% 23 4%
NRAS .49 .42
Wild type 8 89% 79 81% 9 90% 78 81%
Mutated 1 11% 18 19% 1 10% 18 19%
PML-RARA .43 .56
Wild type 3 38% 12 28% 2 25% 13 30%
Mutated 5 62% 31 72% 6 75% 30 70%
Table 5 Incidence of IDH mutations in AML patients from various countries
Country No. IDH1m/all cases (%) No. of IDH1m/CN-AML (%) No. IDH2m/all cases (%) No. of IDH2m/CN-AML (%)
ASIA
Taiwan
Chou W et al.(2010) [18] 27/493 (5.5) 20/227 (8.8) ND ND
China
Zou Y et al.(2010) [28] 4/68 (5.9) ND 4/48 (8.3) ND
Zhang Y et al.(2011) [32] 23/365 (6.3) 6/111 (5.4) ND ND
Lin J et al.(2011) [31] 4/110 (3.6) ND ND ND
Thailand
This study 20/230 (8.7) 11/126 (8.7) 24/230 (10.4) 12/126 (9.5)
EUROPE
‡ [21,23-27,30,41] 6.0-10.9 9.4-16.0 2.0*-10.9 3.2*-15.2
NORTH AMERICA
∫ 2.2-13.7 4.9-16.0 1.3*-19.2 2.4*-19.2
[5,15,19,20,22,29]
*The authors only identified IDH2 R172K but did not include IDH2 R140Q mutation;
† Pediatric acute myeloid leukemia;
‡ All studies reported during 2010-2011;
∫
All studies reported during 2009-2011; ND, not determined
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Page 7 of 10mutation conferred a shorter disease-free survival and
IDH2 R172 mutation contributed to a lower complete
remission or a higher relapse risk compared to wild-type
IDH patients [25,41]. Our study may be limited by a
small number of cases with IDH alterations and a sub-
stantial recruitment of cases with aberrant karyotype
[18,23].
The possible oncogenic role of IDH mutations that
contribute to AML development has been postulated by
available evidence [20,33,34]. By structural and func-
tional analysis, IDH1 and IDH2 mutated cells gained the
neomorphic enzymatic activity creating a condition with
2HG oncometabolite accumulation which promotes
tumorigenesis through inhibiting a cancer-associated
transcription factor such as hypoxia-induced factor
(HIF) [19,20,34]. Moreover, inhibition of normal mye-
loid differentiation and induction of global DNA hyper-
methylation by mutated IDH potentially lead to
leukemogenesis [33], suggesting that IDH genes and
their altered enzymatic pathways may be a potential
new target for future drug development for AML
patients. Intriguingly, IDH1 and IDH2 mutations were
also found in other myeloid disorders such as myelo-
proliferative neoplasms (MPN) and myelodysplastic
s y n d r o m e( M D S )w h i c hh a v eap r o p e n s i t yt oA M L
development, although at a much lower frequency than
AML [42,43]. It was thus speculated that IDH mutations
were likely to be associated with disease transformation
or progression rather than disease initiation [44-46].
In conclusion, IDH1 and IDH2 mutations occur in a
minor subset of newly diagnosed AML patients with a
strong association with normal karyotype, AML-M2
subtype, and NPM1 mutation. No significant correlation
with other mutations such as FLT3, RAS,a n dAML1
could be demonstrated. Larger studies are needed to
confirm the prognostic impact of IDH1 and IDH2 muta-
tions in AML patients from various ethnic backgrounds.
Our results, nevertheless, provide a relevant rationale to
utilize these genomic alterations to better characterize
AML patients in the future.
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